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Introduction
Many severe diseases resulting from infections, such as 
meningitis, dengue, or leprosy, are relatively rare within 
the human population when compared with the often 
ubiquitous nature of the causative infectious agent in 
specific world regions. While antibody responses to these 
organisms can be measured in large percentages of these 
populations, disease leading to hospitalization affects a 
small minority. is has led to the realization that the 
type of host response made to an infectious encounter 
may play a large role in determining the outcome. 
Understanding how most people successfully contain 
these infectious challenges may lead to the development 
of novel therapeutics for those individuals at risk of 
severe disease.
is application of human genetics has proven insight-
ful in those rare humans who are broadly susceptible to 
infections, where Mendelian genetic linkage approaches 
have revealed highly penetrant mutations that cause 
disease. With the advent of genome-wide association 
study (GWAS) technology, the field has been looking to 
see if the lessons learnt can be carried over to more 
common infectious diseases.
Severe combined immune deciency and partial 
immune deciency
e first studies of immune response defects and infec-
tious disease outcomes strongly suggested that infectious 
diseases would have shared pathways to disease. Severe 
combined immune deficiency (SCID) - a genetic disorder 
that affects the adaptive immune system - demonstrates 
the importance of the immune system in protection 
against infection, as patients with SCID quickly succumb 
to life-threatening sepsis from a very wide range of 
infectious agents. e gene responsible for the majority 
of SCID cases, CD132 (the common γ-chain), was 
identified using the traditional linkage approach [1-3]. 
Because the common γ-chain is shared by many cytokine 
receptors (receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and 
IL-21), mutations that result in a non-functional common 
γ-chain cause widespread defects in IL signaling and 
failure of B and T cells to develop and mature. is is a 
rather profound example, and knowledge of the respon-
sible gene has opened avenues for therapeutic inter ven-
tion in cases of X-linked SCID, where gene transfer of the 
normal CD132 appears to be a promising, even curative, 
treatment modality [4,5]. Similar observations and 
clinical conclusions have been made with another form 
of SCID caused by defects in the variable, diversity, 
joining recombination process [6].
Partial immune deficiency, referring to the inactivation 
of a single immune pathway due to genetic mutations in 
one or more members of the network, was initially 
suspected to act in a similar way to the SCID mutations, 
with patients having a predisposition to a wide variety of 
infections. As these mutations are highly penetrant, 
traditional genetic linkage studies have been able to 
isolate the responsible genes and pathways for some of 
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these conditions, many of which have severe or even fatal 
clinical presentations. Notable examples include the 
IFN­γ receptor (IFNGR1) in cases of severe mycobacterial 
infections [7], the lysosomal trafficking regulator (LYST) 
for Chediak­Higashi syndrome [8], and Bruton’s tyrosine 
kinase for X­linked agammaglobulinemia [9,10].
While the immune system has multiple pathways, each 
is thought to be active against a wide range of micro­
organisms. Thus, it is perhaps surprising that the 
spectrum of infection susceptibility for these three genes 
appears to be fairly constrained. For example, IFNGR1 
mutations mainly predispose to mycobacterial infections, 
and LYST and Bruton’s tyrosine kinase mutations mainly 
predispose to predominantly pyogenic bacterial infec­
tions (for example, Streptococcus pyogenes, pneumo­
coccus, and Haemophilus influenzae). This surprising 
finding echoes another example: that of complement 
deficiency and its observed confinement to increased 
susceptibility towards encapsulated bacteria, particularly 
Neisseria spp., despite consistent documentation on the 
importance of the complement pathway in common 
blood pathogen clearance [11,12].
Subtle changes to immune genes as a result of 
genetic polymorphism
In the last 5 years, advances in genomic research have 
enabled the use of the GWAS design, permitting the 
robust identification of host susceptibility genes for 
infectious pathogens in increased detail. Although the 
advent of GWAS in infectious diseases has been slow 
compared with GWAS in many other complex disease 
phenotypes [13,14], this approach has nonetheless allowed 
unprecedented identification (or confirmation) of genes 
associated with susceptibility to the infectious diseases 
studied so far [15­18].
Infectious disease genes identified via the GWAS 
approach have thus far been relatively ‘pathogen specific’, 
with cross­pathogen sharing being the exception rather 
than the rule.
The greatest surprise has related to observations within 
the human leukocyte antigen (HLA) locus, where broad­
based sharing between pathogen groups could be ex­
pected, given the central role played by HLA in immune 
recognition of pathogens and the initiation of immune 
responses. However, recent GWAS have found that while 
different HLA alleles appear to be shared between 
various auto­immune phenotypes (such as psoriasis [19], 
vitiligo [20], or systemic lupus erythematosus [21]), there 
appears to be little evidence of substantial susceptibility 
sharing for HLA between different infectious diseases. 
This disparity is striking even among supposedly ‘similar’ 
pathogen groups: a very strong contribution of the HLA 
locus has been observed for leprosy (Mycobacterium 
leprae) [15,22], but not for tuberculosis (Mycobacterium 
tuberculosis) susceptibility [23,24], highlighting the vast 
complexity of the immune response to diverse pathogens. 
This complexity is further shown in two genetic studies 
of vaccine response: while the HLA is crucial for success 
(or otherwise) for hepatitis B virus vaccination [25], it is 
not the case for H. influenzae type b vaccination [26].
Although findings thus far have suggested that the 
main pathways underlying susceptibility to pathogenic 
infection are pathogen specific, it is nonetheless relevant 
to understand similarities in the infection and invasion 
process for the very diverse pathogens that the human 
body encounters daily. For example, knowledge gleaned 
from the rare primary immune deficiencies has shown 
that defects in extremely central components of the 
immune system result in broad, general susceptibility to 
multiple infectious diseases. Elucidation of the respon­
sible genes and pathways often yields considerable insight 
into disease mechanisms and pathogenesis, and can 
inform medical treatment (a good example being the case 
of X­linked agammaglobulinemia where common anti­
biotic treatments do not suffice, and immunoglobulin 
replacement is necessary). If some of these therapeutic 
findings could be extended to the commoner forms of 
infection that clinicians encounter on a daily basis, this 
could have an immediate public health impact.
Genomic approaches have played a supporting role in 
the identification of potential therapeutic targets. One of 
the virulent capabilities of Neisseria meningitidis is its 
ability to recruit human factor H (encoded by CFH) via 
molecular mimicry [27], thus avoiding complement­
mediated killing of the bacterium. A recently completed 
GWAS on host susceptibility to meningococcal disease 
has shown that genetic polymorphisms within CFH as 
well as CFH­related genes are very strongly associated 
with susceptibility to meningococcal disease [18]. As the 
bacterial factor H­binding protein is now a strong 
meningo coccal vaccine candidate [28], it is clear that 
genomic approaches can be used independently to 
discover or to confirm therapeutic targets identified by 
functional approaches.
Leprosy, tuberculosis, Crohn’s disease, and ulcerative 
colitis have also been the subjects of recent investigations. 
Indeed, genomic approaches have underlined the impor­
tance of the nucleotide­binding oligomerization domain 
containing (NOD)2 signaling cascade in inflammatory 
and infectious diseases. Different members of the path­
way (NOD2, TNFSF15, and RIPK2) have been strongly 
implicated (P < 10­10) in susceptibility to leprosy [15,29], 
as well as Crohn’s disease, which is an inflammatory 
bowel disease with substantial links to infectious agents 
[30,31]. However, observations by us and others [24] do 
not implicate NOD2 pathway members as strongly in 
tuberculosis susceptibility. The same has been observed 
for CARD9 (a member of the extended NOD family of 
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genes), which has been strongly associated with ulcer­
ative colitis susceptibility [32] and functionally implicated 
in tuberculosis [33], but not with leprosy [15].
Another gene observed to be a strong (P < 10­10) 
suscep tibility factor for leprosy is TNFSF15 [15]. The 
exact same SNP (rs6478108) has also been found to be 
strongly associated (P < 10­10) with Crohn’s disease [34]. 
However, the minor allele has been found to be associated 
with increased risk of leprosy, but with decreased risk of 
Crohn’s disease. This suggests that differential regulation 
of the immune response appears to be critical to reach a 
balance between protection from invading pathogens and 
susceptibility to inflammatory disorders, thus highlight­
ing TNFSF15 as a potential therapeutic target in manipu­
lation of the strength of the immune response.
Indeed, the disparity in susceptibility genes for Crohn’s 
disease and ulcerative colitis (different members of the 
pathogen­sensing CARD family are involved: NOD2 for 
Crohn’s, and CARD9 for ulcerative colitis) is likely to 
reflect different sites of pathology, different bacterial 
spectra, and therefore different mechanisms for microbial 
recognition. Strikingly, there is evidence suggesting that 
the downstream, cytokine­mediated pathogenesis path­
ways (for example, those involving IL­23) could be 
common across both diseases [32].
Missing ‘shared susceptibility’?
The majority of evidence collected so far from genomic 
approaches appears to suggest that, barring specific 
exceptions, common host susceptibility to different 
invad ing pathogens appears to be controlled by discrete 
genes and pathways. As genomic approaches are still 
limited in resolution, there is a possibility that truly 
shared mechanisms governing susceptibility across mul­
tiple pathogen groups have yet to be found. This seems to 
be likely in view of the finite number of pathogen­
recognizing receptors available at the first lines of 
defence, coupled with their convergent, downstream 
signaling pathways. An example for ‘shared susceptibility’ 
would be TIRAP, which encodes a common adaptor for 
two major pathogen­sensing receptors (TLR2 and TLR4); 
an inactivating mutation (S180L) within TIRAP appears 
to associate with susceptibility to invasive pneumococcus 
and H. influenzae, as well as Trypanosoma cruzi infec­
tions [26,35,36], with a yet unconfirmed association with 
tuberculosis [37,38].
Considering the evidence now available, there is reason 
to believe that host susceptibility to infection could be 
specific and ‘mechanism dependent’ in terms of pathogen 
recognition and the site of infection, with shared 
common signaling pathways playing an important role 
down stream of pathogen contact points.
A further benefit in the large­scale deployment of 
hypothesis­free genomic approaches is that they could 
help in establishing the etiology of certain autoimmune 
diseases where infectious diseases have long been 
suspected ­ but not confirmed ­ to be a predisposing 
factor. For example, in the case of type 1 diabetes, GWAS 
have implicated an extraordinary number of immune­
related genes, some of which overlap with infection 
pathways, thus lending credence to the above hypothesis.
Genomic approaches have resulted in improved 
treatment strategies for patients with severe and partial 
immune deficiencies by identifying the deficient protein 
component(s), but for many of the common infections, 
due to their complex nature, genomic approaches have not 
yet been as fruitful in informing medical treatment. 
Emerging antibiotic resistance is putting additional 
pressure on research efforts in host and pathogen 
genomics for further improvement of therapeutic strategy 
beyond antimicrobial treatment, but there is hope that this 
research will lead to novel human protein­based therapies.
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